News

Pharnext announces 2020 half-year results

October 15, 2020

Pharnext to Host Research and Development Event Today

October 13, 2020

Pharnext to Host Research and Development Day on October 13, 2020

September 29, 2020

Pharnext and the Charcot–Marie–Tooth Association enter Biomarker Research Collaboration

September 3, 2020

Pharnext appoints Adrian Hepner, MD, PhD as Chief Medical Officer

August 10, 2020

Pharnext announces approval of resolutions at its Annual General Meeting of 17 July 2020

July 20, 2020

Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020

June 11, 2020

Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of CMT1A

June 10, 2020

Pharnext Presents a Business Update Webcast on May 20th, 2020

May 14, 2020

Pharnext Reports Financial Results for Year-End 2019

April 22, 2020

Pharnext and the UHI Méditerranée Infection announce a joint effort to evaluate repurposed drugs for potential use against the COVID-19 Virus

April 22, 2020

Pharnext will hold a Business Overview Webcast on May 20th, 2020

April 21, 2020

Pharnext announces the appointment of David Horn Solomon as Chief Executive Officer

April 16, 2020

Pharnext to organizes a Webcast to take stock of Pharnext, clinical development and research on April 23, 2020 (only avaible in French)

April 7, 2020

Pharnext announces identification of a large set of frequently prescribed drugs to be repurposed for fighting COVID-19, using its Pleotherapy™ platform

March 23, 2020

PXT3003 for the treatment of CMT1A granted Promising Innovative Medicine (PIM) Designation by UK MHRA

March 18, 2020

Pharnext raises € 7.7 million in a private placement

March 5, 2020

PXT3003: Encouraging Data from Open-Label Phase 3 Extension Study in CMT1A

January 6, 2020

Pharnext establishes an equity line facility with Kepler Cheuvreux

November 19, 2019

Pharnext announces 2019 half-year results

October 16, 2019

Pharnext and Galapagos successfully achieved their research and development collaboration

September 9, 2019

Pharnext provides U.S. regulatory update on PLEODRUG PXT3003 in CMT1A

August 30, 2019

Video of Peter Collum, new Chief Financial Officer and Chief Business Officer

June 26, 2019

Pharnext Announces the Apppointment of Peter Collum as Chief Financial Officer and Chief Business Officer

June 26, 2019

Pharnext confirms its eligibility to the French SME equity savings plan "PEA-PME" (only available in French)

May 14, 2019

Pharnext reports financial results for Year-End 2018

April 24, 2019

Pharnext to reinforce equity capital by conversion of convertibles bonds

March 6, 2019

Pharnext to host a KOL investors event focused on CMT in Paris (only availbable in French)

February 20, 2019

PXT3003: FDA Fast Track designation for the treatment of CMT1A

February 4, 2019

Pharnext raises €15 million without discount

January 23, 2019

PXT3003: Early therapeutic effects in a transgenic rat model of CMT1A

January 17, 2019

Susanne Dorn and Serge Fitoussi appointed as Chief Regulatory Officer and Chief Medical Officer

January 14, 2019

Pharnext to present at BMO 2018 Prescriptions for Success Healthcare Conference

December 12, 2018

Pharnext announces 2018 half-year results

October 25, 2018

PXT3003: Positive topline results from pivotal Phase 3 trial for treatment of CMT1A

October 16, 2018

Pharnext and Vitaccess launch International CMT&Me Observational Study

September 10, 2018

David Stout joins Pharnext’s Board of Directors

September 17, 2018

Pharnext to host a key opinion leader symposium focused on CMT1A

July 30, 2018

Pharnext announces issuance of composition of matter patents covering PLEODRUG™ PXT3003 and PXT864

July 18, 2018

PXT3003: EMA agrees with Pharnext’s pediatric investigation plan

July 10, 2018

PXT3003: Top-line results from Phase 3 trial in CMT1A by October 2018

June 21, 2018

PXT3003: Granted priority review by the China FDA

June 14, 2018

Pharnext announces €20,5 million bond loan

June 13, 2018

Pharnext to present latest data on its two lead assets at several international scientific conferences

June 11, 2018

Pharnext transfers its liquidity contrat (only available in French)

June 5, 2018

Pharnext appoints Amit Kohli as Chief Operating Officer

April 26, 2018

Pharnext to showcase PLEOTHERAPY™ R&D platform at the Global Orphan Drug Conference

April 19, 2018

Pharnext confirms its continued eligibility to the PEA-PME (only available in French)

April 17, 2018

Pharnext reports financial results for Year-End 2017

April 12, 2018

Pharnext successfully raises €16 million via private placement

April 11, 2018

Pharnext to present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference

March 29, 2018

Pharnext to attend Shareholders meetings in Bordeaux and Lyon (only in French)

February 26, 2018

Pharnext to attend Shareholders meeting in Paris (only in French)

February 19, 2018

PXT3003: Status of ongoing Phase 3 trial to be featured at the Francophone Peripheral Nerve Society conference

January 18, 2018

Philippe Chambon joins Pharnext’s Board of Directors

January 2, 2018

PXT3003: Successful intermediate analyses for Phase 3 trial in CMT1A

November 29, 2017

Pharnext to Attend November Investor Conferences

November 2, 2017

PXT864: new synergy data to be presented at CTAD in Boston, USA

October 30, 2017

PXT3003: Featured at the Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit

October 26, 2017

Pharnext announces first half 2017 results

October 19, 2017

Pharnext to present at 4th International Neurotech Investing and Partnering Conference

September 28, 2017

Pharnext amends the protocol of the international pivotal Phase 3 trials of PXT3003 for CMT1A

September 18, 2017

Pharnext to Present at 7th Annual CEC Capital Summit

September 13, 2017

PXT3003: Featured at the AANEM 2017 Annual Meeting

September 7, 2017

PXT3003: DSMB recommends continuing the ongoing Phase 3 Trial of PXT3003 for CMT1A

September 6, 2017

Pharnext to present at Rodman & Renshaw 19th Annual Global Investment Conference

September 5, 2017

Pharnext to hold its first satellite symposium on CMT1A at Neuromuscular Days in Marseille

August 31, 2017

PXT864: Data presented at the Alzheimer's Association International Conference 2017

July 10, 2017

PXT3003: Status of ongoing Phase 3 trial to be featured at the 2017 Peripheral Nerve Society Meeting

June 27, 2017

Pharnext to showcase PLEOTHERAPY™ platform at Drug Repositioning, Repurposing and Rescue Conference

June 20, 2017

Strategic partnership with Tasly, a leading Chinese pharmaceutical group

May 10, 2017

Pharnext reports year end 2016 financial results

April 26, 2017

Pharnext confirms its continued eligibility to the PEA-PME

April 11, 2017

Reclassification of historical investor’s shares - Strengthening the position of core shareholders

March 29, 2017

PXT864: New synergy data presented at AD/PD™ 2017 Conference in Vienna, Austria

March 29, 2017

PXT3003: initiation of Phase 3 extension study PLEO-CMT-FU for CMT1A

March 16, 2017

R&D agreement with Galapagos to generate a new pipeline of synergistic drug combinations

March 9, 2017

Pharnext to present at 2017 BIO & CEO Investor Conference in New York, USA

February 7, 2017

Pharnext evaluates the clinical scale Charcot-Marie-Tooth Neuropathy Score

February 2, 2017

Pharnext winner of the Best Life-Sciences IPO France 2016 Award

January 17, 2017

Pharnext to Attend January Investor Conferences

January 4, 2017

Amendment to the liquidity contract and annual update

January 3, 2017

PXT3003: PLEO-CMT Phase 3 Trial enrollment completed

December 20, 2016

PXT864: Positive Phase 2 Data in Alzheimer’s Disease presented at CTAD in San Diego, USA

December 13, 2016

PXT864: Phase 2 data in Alzheimer's disease will be featured at CTAD in San Diego, USA

December 1, 2016

PXT3003: DSMB recommends continuing the PLEO-CMT study

November 17, 2016

Pharnext to attend Jefferies 2016 Healthcare Conference in London, UK

November 3, 2016

Pharnext announces first half 2016 results

October 27, 2016

PXT3003 featured at 2016 International CMT meeting

September 1, 2016

René Goedkoop and François Chamoun appointed as Chief Medical Officer and General Counsel

July 26, 2016

Implementation of a liquidity contract with French broker Gilbert Dupont

July 18, 2016

Successful completion of the IPO - Pharnext raises €31 million on Euronext Alternext Stock Exchange in Paris

July 13, 2016

Pharnext launches its Listing on the Euronext Alternext Stock Exchange in Paris

June 27, 2016

Registration of the document de base as part of a planned IPO on Euronext’s Alternext market in Paris

June 3, 2016